Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.

@article{Manosuthi2007NevirapineLA,
  title={Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.},
  author={Weerawat Manosuthi and Kiat Ruxrungtham and Sirirat Likanonsakul and Wisit Prasithsirikul and Yaowarat Inthong and Thanongsri Phoorisri and Somnuek Sungkanuparph},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2007},
  volume={44 1},
  pages={141-4}
}
Seventy patients with human immunodeficiency virus (HIV) and tuberculosis coinfection who initiated nevirapine-based antiretroviral therapy and had trough nevirapine levels determined while receiving rifampicin were enrolled in a study. After discontinuation of rifampicin therapy, mean nevirapine levels (+/- standard deviation) increased from 5.4+/-3.5 mg/L to 6.4+/-3.4 mg/L (P=.047), but no nevirapine-related adverse events occurred. There was no statistically significant difference in 60-week… CONTINUE READING